Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus.
We evaluated the progression of microangiopathic lesions in 22 type I diabetic patients with residual C-peptide excretion and in 22 type I diabetic patients matched for age at onset and disease duration without residual C-peptide excretion. We also wished to elucidate whether certain HLA-DR phenotypes were associated with preserved insulin secretory activity and/or microvascular lesions. The two groups of patients were investigated in 1984 and 1985. In the previous report, we observed less frequent signs of early microangiopathic lesions in association with a lower HbA1c in the group with a detectable urinary C-peptide excretion. The HbA1c level has been measured regularly (7-12 times) since the initial investigation; the mean value was lower in the patient group with residual C-peptide excretion than in the non-C-peptide group (p = 0.01). Nine of the patients in the group without urinary C-peptide excretion had increased severity of retinopathy, but only two in the group with urinary C-peptide excretion (p = 0.04) had progression of retinopathy. Incipient and/or manifest albuminuria was observed in six of the nonexcretor group and one of the C-peptide excretors. Four of the patients were receiving antihypertensive treatment and three others had a diastolic blood pressure greater than or equal to 90 mmHg in the non-C-peptide excretor group as compared with one with a pressure greater than or equal to 90 mmHg in the C-peptide excretor group.(ABSTRACT TRUNCATED AT 250 WORDS)
Sjöberg
S
S
Department of Medicine, Huddinge Hospital, Karolinska Institute, Sweden.
Gjötterberg
M
M
Berglund
L
L
Möller
E
E
Ostman
J
J
D000328:Adult; D000419:Albuminuria / Q000097:blood; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis*; D002096:C-Peptide / Q000652:urine*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000378:metabolism*; D003930:Diabetic Retinopathy / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000032:analysis; D006441:Hemoglobin A / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008297:Male; D013997:Time Factors
D000959:Antihypertensive Agents; D001786:Blood Glucose; D002096:C-Peptide; D006684:HLA-DR Antigens; D006441:Hemoglobin A